Stockreport

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why [Yahoo! Finance]

2seventy bio, Inc.  (TSVT) 
PDF The company is developing and commercializing its chimeric antigen receptor (CAR) T cell immunotherapy, Abecma (idecabtagene vicleucel), in partnership with drug giant, [Read more]